The main strategies to improve permeability via EPR are directed toward dilating tumor vasculature, such as with nitric oxide-mediated vasodilation (angiotensin-converting-enzyme inhibitors, nitroglycerin, etc.), prostaglandin I2 agonists (105), tumor necrosis factor-a (106), or increasing systemic blood pressure by intraarterial administration of angiotensin II (107). The gene discussed is ACE; the disease is neoplasm.